

> MULTIPLE MYELOMA (MM)


# PLASMA CELL DYSCRASIAS

MULTIPLE MYELOMA (MM)

定義 and 流行病學 (_NEJM_ 2011;364:1046)

• Malignant neoplasm of **plasma cells** producing a monoclonal Ig = “**M protein**”

• ~27,000 new cases/y; median age at diagnosis 69 y; more common in African Americans

臨床表現 (CRAB criteria and other less common features)

• Hyper**C**alcemia due to ↑ osteoclast activity

• **R**enal disease: multiple mechanisms include toxic effect of filtered light chains → _renal failure_ (cast nephropathy) or _type II RTA;_ amyloidosis or light chain deposition disease → _nephrotic syndrome;_ hypercalcemia, urate nephropathy, type I cryoglobulinemia

• **A**nemia (normocytic) due to bone marrow involvement; rarely, may see AIHA

• Lytic **B**one lesions due to ↑ osteoclast activity → pathologic fx

• Recurrent infxns due to relative hypogammaglob. (clonal plasma cells suppress 正常 Ig)

• Neurologic: cord compression; POEMS (polyneuropathy, organomegaly, endocrinopathy, M protein, skin changes) syndrome

• Hyperviscosity: usually when IgM >4 g/dL, IgG >5 g/dL, or IgA >7 g/dL

• Coagulopathy: seen in amyloid due to binding & depletion of Factor X

• AL amyloidosis (see “Amyloidosis”)

Diagnostic and staging evaluation (_Lancet Onc_ 2014;15:e538)

• **MM criteria:** clonal BM plasma cells ≥10% or bx-proven plasmacytoma and ≥1 myeloma-defining event:

(a) myeloma-related organ or tissue impairment (**ROTI**) = lytic bone lesions, Ca >11 mg/dL, Cr >2 mg/dL, or Hb <10 g/dL

(b) any of the following biomarkers: BM plasma cells ≥60%, serum free light chain (FLC) ratio ≥100:1, >1 focal lesion on MRI studies

• **Variants**

Smoldering MM: M protein >3 g/dL or plasmacytosis >10%, but no myeloma-defining event or amyloidosis; see below under MGUS for approach

Solitary bone plasmacytoma: 1 lytic lesion without plasmacytosis or other ROTI

Extramedullary (nonosseous) plasmacytoma: usually upper respiratory tract

Plasma cell leukemia: plasma cell count >2000/µL in peripheral blood

Nonsecretory MM (~2% of MM 病人): no M protein, but marrow plasmacytosis & ROTI

• Ddx of M component: MM, MGUS (see below), CLL, lymphoma, sarcoidosis, RA. Polyclonal hypergam can be seen in inflammatory states: HIV, rheumatic dis., cirrhosis.

• Peripheral smear → rouleaux (see insert); ✔ Ca, alb, Cr; ↓ anion gap, ↑ globulin, ↑ ESR

• **Protein electrophoresis and immunofixation**

**serum protein electrophoresis (SPEP):** quantitates M component; ⊕ in >80% of 病人

urine protein electrophoresis (UPEP): detects 病人 who secrete only light chains (= Bence Jones proteins), which are filtered rapidly from the blood

immunofixation: shows component is monoclonal and identifies Ig type → IgG (50%), IgA (20%), IgD (2%), IgM (0.5%), light chain only (20%), nonsecretors (<5%)

**serum FLC assay:** important for dx (esp. light chain–only 病人) and f/up response to Rx

• β2\-microglobulin and LDH levels reflect tumor burden

• **BM bx cytogenetics:** normal karyotype better than 異常. **Standard risk** = hyperdiploidy or t(11;14); **high risk** = hypodiploidy, del. 17p13 (~10% of 病人), t(4;14) & t(4;16)

• **Skeletal survey** (plain radiographs) to identify lytic bone lesions and areas at risk for pathologic fracture; _bone scan is not useful for detecting lytic lesions._ Increasingly, whole-body PET-CT (scalp to toe) or MRI is being used to detect bone lesions.

![](https://i.imgur.com/nafG8Vs.jpg)

\*Consider R-ISS incl chrom 異常 & LDH (_JCO_ 2005;23:3412 & 2015;61:2267).

治療 (_NEJM_ 2016;375:754 & 1319; 2018;378:518 & 379:1811)

• Decisions generally dictated by _risk stratification_ and _transplant eligibility_

• Rx incl. **proteasome inhibitors:** bortezomib (V), carfilzomib (K), ixazomib (I); **immunomodulators:** lenalidomide (R), thalidomide (T), pomalidomide (P); **immunotherapy:** daratumumab (anti-CD38, Dara), elotuzumab (Elo)

Other active drugs incl. dexamethasone (D), melphalan (M), panobinostat, cyclophosphamide (CYC);

CAR-T cells (anti-BCMA) promising (_NEJM_ 2015;373:621 & 1207; 380:1726; _Lancet_ 2016;387:1551)

• Induction Rx with best response rate: proteasome inhib (V or K) + immunomod (eg, R). Triplet Rx ↑ OS vs. double (_Lancet_ 2017;389:519). RVD most common regimen in US; KRD if high-risk (_NEJM_ 2014;371:906 & 2016;374:1621). Dara-RD an option (_NEJM_ 2019;380:2104).

• If _not_ transplant eligible: **induction chemo** ↑ survival, not curative; consider maint chemo

• If transplant _eligible:_ after induction chemo then **high-dose melphalan** + **auto-HSCT.** Not curative, but ↑ progression-free survival (PFS) vs. chemo alone (_NEJM_ 2014;371:895, _Lancet Onc_ 2015;16:1617). Offer if good perf. status & no prohibitive comorbid. Maint Rx with R improves PFS/OS (_NEJM_ 2014;371:10). Timing of HSCT (upfront vs. relapse) debatable.

• Relapsed/refractory: based on prior response & HSCT eligibility: HSCT (if good prior response, no prior HSCT), Elo-PD, Dara-PD; rarely use Allo-SCT.

• Local radiation for solitary or extramedullary plasmacytoma

• Adjunctive Rx: _bone:_ **bisphosphonates** (_JCO_ 2007;25:2464), XRT for sx bony lesions

_renal:_ avoid NSAIDs & IV contrast; consider plasmapheresis for acute renal failure

_hyperviscosity syndrome:_ plasmapheresis; _infxns:_ consider IVIg for recurrent infections

• Common **toxicities** of Rx: melphalan → myelosuppression; lenalidomide → low plts & thromboembolism; bortezomib → periph. neuropathy; steroids → hyperglycemia, infxn

MONOCLONAL GAMMOPATHY OF UNCERTAIN SIGNIFICANCE (MGUS)

定義 and 流行病學 (_NEJM_ 2006;354:1362 & 355:2765)

• M prot. <3 g/dL, marrow plasmacytosis <10%, neither myeloma ROTI nor amyloidosis

• Prevalence ~3% in population >50 y of age, ~5% in >70 y of age, 7.5% in >85 y of age

Management

• ✔ CBC, Ca, Cr, SPEP, serum free light chains, UPEP with immunofixation (to exclude MM)

• Close observation: repeat SPEP in 6 mo, then yearly thereafter if stable

Prognosis (_NEJM_ 2018;378:241)

• ~1%/y or ~25% lifetime risk → MM, WM, amyloidosis, or malign. lymphoproliferative dis.

• Abnormal serum free light chain ratio & M protein ≥1.5 g/dL: ↑ risk of progression to MM

Smoldering MM (not MGUS, but variant of MM that req no Rx)

• Need whole-body MRI or PET-CT to rule out occult bone lesions

• Risk of prog. 10%/y, depends on \[M protein\], subtype, FLC ratio. No defined role for Rx yet.

WALDENSTRÖM’S MACROGLOBULINEMIA (WM)

定義 (_Blood_ 2009;114:2375; _NEJM_ 2012;367:826)

• B-cell neoplasm (lymphoplasmacytic lymphoma) that secretes monoclonal IgM

• 91% with _MYD88_ (NF-κB pathway) L265P mut., may distinguish from MM

• _No evidence of bone lesions_ (IgM M component + lytic bone lesions = “IgM myeloma”)

臨床表現

• **Fatigue** from anemia is most common sx

• **Tumor infiltration:** BM (cytopenias), hepatomegaly, splenomegaly, lymphadenopathy

• **Circulating monoclonal IgM**

### Hyperviscosity syndrome (~15%): _Neurologic:_ blurred vision (“sausage” retinal veins), HA, dizziness, Δ MS. _Cardiopulmonary:_ congestive heart failure, pulm. infiltrates.

Type I **cryoglobulinemia** → **Raynaud’s phenomenon**

Platelet dysfxn → mucosal bleeding

• **IgM deposition** (skin, intestine, kidney); amyloidosis and glomerulopathy

• **Autoantibody activity of IgM:** _Chronic AIHA_ (prominent **rouleaux;** 10% Coombs’ ⊕ = AIHA). _Peripheral neuropathy:_ may be due to IgM against myelin-associated glycoprotein.

Diagnostic evaluation

• SPEP + immunofixation with IgM >3 g/dL; 24-h urine for UPEP (only 20% have ⊕ UPEP)

• Bone marrow biopsy: ↑ plasmacytoid lymphocytes; β2\-microglobulin for prognostic eval

• **Relative serum viscosity:** ratio serum viscosity to H2O (nl 1.8); hyperviscosity when >5–6

治療

• Hyperviscosity: **plasmapheresis**

• Sx (eg, prog. anemia): rituximab ± chemo (eg, bendamustine, Cy, etc.); data for rituximab + ibrutinib (_NEJM_ 2018;378:2399). Everolimus or HSCT in salvage.
